RCT: Melatonin does not improve appetite or other symptoms in patients with advanced cancer and cachexia
Source: JCO
Area: News
The Journal of Clinical Oncology has featured a study evaluating the safety and efficacy of melatonin for appetite improvement in patients with cancer cachexia.
The randomised, double-blind, placebo-controlled, 28-day trial involved patients with advanced lung or gastrointestinal cancer (GI) cancer, with appetite scores ? 4 on a 0 to 10 scale (10 = worst appetite), and a history of weight loss ? 5%. Assessments included weight, symptoms by the Edmonton Symptom Assessment Scale, and quality of life by the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.
The researchers reported that after an interim analysis of 48 patients, the study was closed for futility - there were no statistically significant differences between groups for appetite (P = 0.78) or other symptoms, weight (P = 0.17), FAACT score (P = 0.95), toxicity, or survival from baseline to day 28.
The researchers conclude that in cachectic patients with advanced ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Anorexia | Cancer | Cancer & Oncology | Drugs & Pharmacology | Eating Disorders & Weight Management | Gastroenterology | Melatonin | Statistics | Study | Toxicology | Weight Loss